Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland

This study has been completed.
Sponsor:
Collaborators:
Society of Alcoholism and other Addictions
Information provided by (Responsible Party):
Helen Pettinati, National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT01100853
First received: April 7, 2010
Last updated: November 25, 2013
Last verified: November 2013

April 7, 2010
November 25, 2013
May 2010
February 2013   (final data collection date for primary outcome measure)
  • Number Negative Urines (Proportion Negative Urines) [ Time Frame: 24 Weeks ] [ Designated as safety issue: No ]
  • Number Negative Urines (Proportion Negative Urines) Amphetamine [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Between group proportions of Amphetamine negative urine tests. [ Time Frame: 24 Weeks ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01100853 on ClinicalTrials.gov Archive Site
  • Amphetamine Craving Scale [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    The Amphetamine Craving Scale is a visual analogue scale, which is scored by indicating the level of craving on a 100 mm line, where 0 is no craving at all and 100 is the highest level of craving experienced. Scores are derived from measuring their placement on the line, yielding scores from 0 to 100.
  • Beck Depression Inventory [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    The Beck Depression Inventory is a self-administered questionnaire that assess the severity of depressive symtpoms. It consists of 21 items about how the subject has been feeling in the last week, and each item has a set of at least four possible answer choices, ranging in intensity, yielding scores from 0-3, with a total possible score of 63. Higher scores indicate more severe depressive symptoms.
  • Risk Assessment Battery [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    The Risk Assessment Battery is a 41 item self-report questionnaire that assess risk behaviors related to HIV infection over the past 6 months. The measure yields a Drug risk score ranging from 0-22 and a Sex risk score ranging from 0-18, with higher scores indicating more risk; these scores are added to yield a Total RAB score ranging from 0-40. This total scores is then divided by 40 to yield a RAB Scale Score from 0-1.
  • Prior Admissions to Vogur Hospital [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    Number of prior admissions due to substance dependence. The term "prior admissions" refers to admissions before enrollment, thus Baseline is the appropriate Time Frame.
Time to relapse: HIV risk behavior; Treatment retention; Amphetamine craving; Use of amphetamine and other drugs; Criminal activity; Depression; Quality of Life [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland
Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland

Until positive results were found with oral naltrexone, no medication has been effective against amphetamine dependence. The primary aim of this pilot study is to replicate the findings of the Swedish team that showed oral Naltrexone prevented relapse to amphetamine addiction and to extend their results by randomizing treatment-seeking amphetamine addicted patients to a 6 month course of VIVITROL (naltrexone for extended-release injectable suspension) or VIVITROL placebo. Patients in each group will receive drug counseling. VIVITROL is administered monthly and may be a better test of efficacy than tablets that must be taken daily.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Amphetamine Dependence
Drug: VIVITROL injection and VIVITROL Placebo Injection , 24 weeks
Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
  • Active Comparator: Extended release VIVITROL injection 380 mg, 24 weeks
    Efficacy of 24 week course of Extended Release VIVITROL 380 mg with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
    Intervention: Drug: VIVITROL injection and VIVITROL Placebo Injection , 24 weeks
  • Placebo Comparator: VIVITROL placebo injection, 24 weeks
    Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
    Intervention: Drug: VIVITROL injection and VIVITROL Placebo Injection , 24 weeks
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
February 2013
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age 18 or above;
  2. Diagnosis of amphetamine dependence as defined by DSM-IV-TR with 10 or more days of amphetamine use in the past month, and patient and clinician identify amphetamine dependence as the main problem;
  3. Abstinent from substances (alcohol, amphetamines, cannabinoid, cocaine, hallucinogens, opioids, benzodiazepines [unless used to treat alcohol withdrawal] for at least 7 days prior to receiving study drug or placebo;
  4. Provision of telephone numbers/contacts of three or more people that are likely to know where can be located if unable to be contacted directly;
  5. Successfully complete 7-10 day assessment and study baseline measures at Vogur

Exclusion Criteria:

  1. Any liver test >5 times the top limit of normal; Physiologically dependent on opioids or other substances (nicotine excepted) at time of admission to Vogur;
  2. Suspected or known concomitant use of opioid analgesics, positive opioid urine drug test or positive naloxone challenge:
  3. Schizophrenia, Bipolar I or other non-substance related psychotic disorder; Severely depressed, suicidal or homicidal: Dementia: Inability to understand the informed consent;
  4. Planning to move from the Reykjavík area or enter jail within the next 12 months;
  5. Likely to receive opioid analgesics in next 6 months associated with possible or scheduled surgery or procedure;
  6. Known hypersensitivity to naltrexone, polyactide-co-glycolide (PLG); carboxymethylcellulose, or any other component of the diluent;
  7. Female subjects who are pregnant or lactating, or of child bearing potential who are not using acceptable methods of birth control;
  8. A body habitus that precludes use of the customized needle for intramuscular injection, based on clinical judgment;
  9. Use of an investigational agent in the past 30 days
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Iceland
 
NCT01100853
811095, P50DA012756, 2009-013647-10
No
Helen Pettinati, National Institute on Drug Abuse (NIDA)
University of Pennsylvania
  • National Institute on Drug Abuse (NIDA)
  • Society of Alcoholism and other Addictions
Principal Investigator: Helen Pettinati, Ph.D University of Pennsylvania
Principal Investigator: George Woody, M.D. University of Pennsylvania
University of Pennsylvania
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP